- active not recruitingPHASE2, PHASE3
Setrusumab vs Placebo for Osteogenesis Imperfecta
This study is testing a new medicine, Setrusumab, for people aged 5-25 with Osteogenesis Imperfecta (brittle bone disease). It aims to see if Setrusumab can reduce bone fractures compared to a dummy treatment (placebo) and find the best dose.
United States · Australia · Canada - active not recruitingPHASE3
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
This study is looking at a new medicine called romosozumab for children and teenagers aged 5-17 with Osteogenesis Imperfecta (brittle bone disease). It wants to see if romosozumab is better than existing bisphosphonate medicines at preventing broken bones and improving bone strength over 12 months.
United States · Australia · Austria - ongoing, recruitingTherapeutic use (Phase IV)
Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid
This study looks at different treatments for Osteogenesis Imperfecta (brittle bone disease) in adults. Researchers want to understand which treatments best reduce bone breaks over several years. It's an ongoing study tracking real-world results.
France · Ireland · Netherlands